Epidemiology of hospitalisations caused by rubella in the general population in Spain (1997-2006)
DOI:
https://doi.org/10.23938/ASSN.0533Keywords:
Rubéola. Hospitalización. España. VacunasAbstract
Background. Rubella is benign in children, but in pregnant women it can produce Congenital Rubella Syndrome (CRS) with severe consequences for the foetus. In spite of vaccination coverage in Spain being above 95%, isolated cases and outbreaks continue to occur. The aim of this study is to estimate the incidence of hospitalisations due to rubella in Spain (1997-2006). Methods. Utilising the basic minimum dataset (National System of Epidemiological Surveillance) we calculated: rate of hospitalisation, average stay and cost. Results. There were 267 hospitalisations, amongst them 144 due to rubella during pregnancy, 1 due to CRS and 8 due to encephalomyelitis. The overall rate of hospitalisation was 0.065 per 105 inhabitants (IC95%=0.0649-0.0654). The average stay was 3 days. The average cost of a hospitalisation was 2,082 €, and if complicated by encephalomyelitis it rose to 8.191 €. Conclusion. There continue to be hospitalisations due to rubella, basically due to problems in gestation and to complications in the existing susceptible population group.Downloads
References
1. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003 Nov;14(5):306-15.
https://doi.org/10.1590/S1020-49892003001000005
2. Eliminating measles and rubella and preventing congenital rubella infection. 10 WHO European Region strategic plan 2005-2010 WHO Regional Office for Europe 2005.
3. Reef SE, Redd SB, Abernathy E, Zimmerman L, Icenogle JP. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission. Clin Infect Dis 2006 Nov 1;43 Suppl 3:S126-S132.
https://doi.org/10.1086/505944
4. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994 Nov 24;331(21):1397-402.
https://doi.org/10.1056/NEJM199411243312101
5. Plotkin SA. Rubella eradication. Vaccine 2001 May 14;19(25-26):3311-9.
https://doi.org/10.1016/S0264-410X(01)00073-1
6. Servicio de Vigilancia Epidemiológica, Centro Nacional de Epidemiología. Plan Nacional de Eliminación del Sarampión. España 2006. Ministerio de Sanidad y Consumo; 2007.
7. World Health Organization. Surveillance guidelines for measles and congenital rubella infection in the Who European Region. http://www.euro.who.int/document/E82183.pdf 2003.
8. Amela C, Pachon I, De Ory F. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Eur J Epidemiol 2003;18:71-9.
https://doi.org/10.1023/A:1022567811765
9. Martinez-Torres AO, Mosquera MM, Sanz JC, Ramos B, Echevarria JE. Phylogenetic analysis of rubella virus strains from an outbreak in Madrid, Spain, from 2004 to 2005. J Clin Microbiol 2009 Jan;47(1):158-63.
https://doi.org/10.1128/JCM.00469-08
10. Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002;80(4):264-70.
11. Rivero Cuadrado A. El conjunto mínimo básico de datos en el SNS: inicios y desarrollo actual. Rev Fuentes Estadísticas 2000;49:18-9.
12. Schreyögg J, Stargardt T, Tiemann O, Busse R. Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries. Health Care Manag Sci 2006;9:215-23.
https://doi.org/10.1007/s10729-006-9040-1
13. Lopez-de-Andres A, Jimenez-Garcia R, Carrasco-Garrido P, varo-Meca A, Galarza PG, de Miguel AG. Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005. BMC Public Health 2008;8:109.
https://doi.org/10.1186/1471-2458-8-109
14. Centers for Disease Control and Prevention. Rubella. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editors. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington DC: Public Health Foundation; 2008.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
